Detalles de la búsqueda
1.
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Cancer Immunol Immunother
; 66(1): 91-102, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27815572
2.
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
Ann Hematol
; 96(10): 1681-1691, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28762081
3.
A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy.
Leuk Lymphoma
; 61(9): 2136-2144, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32449636
4.
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.
Leuk Lymphoma
; 55(8): 1774-80, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24237446
5.
Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013.
Leuk Lymphoma
; 58(5): 1219-1223, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27894205
Resultados
1 -
5
de 5
1
Próxima >
>>